Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CNMD Stock Forecast 2026-2027
$39.08
Current Price
$1.20B
Market Cap
Buy 0
Hold 6
Sell 0
Wall St Analyst Ratings
Distance to CNMD Price Targets
+33.1%
To High Target of $52.00
+10.0%
To Median Target of $43.00
-0.2%
To Low Target of $39.00
CNMD Price Momentum
+1.6%
1 Week Change
+8.7%
1 Month Change
-19.6%
1 Year Change
-3.7%
Year-to-Date Change
-36.0%
From 52W High of $61.08
+17.7%
From 52W Low of $33.21
📊 TOP ANALYST CALLS
Did CNMD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if CONMED is one of their latest high-conviction picks.
Latest CNMD Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, CNMD has a neutral consensus with a median price target of $43.00 (ranging from $39.00 to $52.00). The overall analyst rating is Buy (6.0/10). Currently trading at $39.08, the median forecast implies a 10.0% upside. This outlook is supported by 0 Buy, 6 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Travis Steed at B of A Securities, projecting a 33.1% upside. Conversely, the most conservative target is provided by Matt O'Brien at Piper Sandler, suggesting a 0.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CNMD Analyst Ratings
0
Buy
6
Hold
0
Sell
CNMD Price Target Range
Low
$39.00
Average
$43.00
High
$52.00
Current: $39.08
Latest CNMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CNMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 17, 2026 | Piper Sandler | Matt O'Brien | Neutral | Downgrade | $39.00 |
| Jan 29, 2026 | Wells Fargo | Vik Chopra | Equal-Weight | Maintains | $42.00 |
| Jan 29, 2026 | Needham | Mike Matson | Hold | Reiterates | $N/A |
| Dec 8, 2025 | B of A Securities | Travis Steed | Neutral | Maintains | $52.00 |
| Nov 6, 2025 | Wells Fargo | Vik Chopra | Equal-Weight | Maintains | $47.00 |
| Nov 6, 2025 | JP Morgan | Robbie Marcus | Neutral | Maintains | $52.00 |
| Nov 6, 2025 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $55.00 |
| Jul 31, 2025 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $68.00 |
| Jun 12, 2025 | Needham | Mike Matson | Hold | Downgrade | $61.00 |
| May 1, 2025 | Needham | Mike Matson | Buy | Maintains | $61.00 |
| May 1, 2025 | Wells Fargo | Vik Chopra | Equal-Weight | Maintains | $57.00 |
| May 1, 2025 | JP Morgan | Robbie Marcus | Neutral | Maintains | $58.00 |
| Apr 28, 2025 | Stifel | Rick Wise | Hold | Downgrade | $55.00 |
| Feb 6, 2025 | Wells Fargo | Vik Chopra | Equal-Weight | Maintains | $70.00 |
| Feb 6, 2025 | JP Morgan | Robbie Marcus | Neutral | Downgrade | $70.00 |
| Feb 6, 2025 | Stifel | Rick Wise | Buy | Maintains | $75.00 |
| Feb 6, 2025 | Needham | Mike Matson | Buy | Maintains | $91.00 |
| Oct 31, 2024 | Needham | Mike Matson | Buy | Reiterates | $97.00 |
| Oct 4, 2024 | Needham | Mike Matson | Buy | Reiterates | $97.00 |
| Aug 1, 2024 | Stifel | Rick Wise | Buy | Maintains | $76.00 |
CONMED Corporation (CNMD) Competitors
The following stocks are similar to CONMED based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CONMED Corporation (CNMD) Financial Data
CONMED Corporation has a market capitalization of $1.20B with a P/E ratio of 25.9x. The company generates $1.37B in trailing twelve-month revenue with a 3.4% profit margin.
Revenue growth is +7.9% quarter-over-quarter, while maintaining an operating margin of +7.3% and return on equity of +4.7%.
Valuation Metrics
Market Cap
$1.20B
Enterprise Value
$2.05B
P/E Ratio
25.9x
PEG Ratio
-0.5x
Price/Sales
0.9x
Growth & Margins
Revenue Growth (YoY)
+7.9%
Gross Margin
+58.5%
Operating Margin
+7.3%
Net Margin
+3.4%
EPS Growth
-50.4%
Financial Health
Cash/Price Ratio
+3.4%
Current Ratio
2.1x
Debt/Equity
85.9x
ROE
+4.7%
ROA
+3.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
CONMED Corporation (CNMD) Business Model
About CONMED Corporation
What They Do
Develops medical technology for surgical procedures.
Business Model
CONMED Corporation generates revenue by designing, manufacturing, and distributing surgical equipment and medical devices, primarily in orthopedic and general surgery. The company serves a diverse range of healthcare professionals and settings, leveraging sales subsidiaries and distribution networks across approximately 100 countries to reach its customers.
Additional Information
The company focuses on advanced solutions that enhance surgical efficiency and improve patient outcomes, particularly in value-based care environments. Its product offerings include specialized technologies like the AirSeal insufflation system and a variety of instruments for both orthopedic and general surgeries.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
3,900
CEO
Mr. Patrick J. Beyer
Country
United States
IPO Year
1990
Website
www.conmed.comCONMED Corporation (CNMD) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Here's Why You Should Retain CONMED Stock in Your Portfolio Now
CNMD's high-margin platforms, supply-chain recovery and margin expansion plans support growth, though tariffs and portfolio shifts weigh on near-term results.
Apr 09, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
CNMD's growth is supported by high-margin platforms and supply-chain recovery, but tariffs and portfolio shifts may impact near-term results.
Why It Matters
CNMD's growth potential is bolstered by high-margin platforms and supply-chain recovery, but tariffs and portfolio changes may hinder short-term profits, affecting investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
CONMED Corporation (NYSE: CNMD) will report Q1 2026 financial results on April 29, 2026, after market close, followed by a conference call at 4:30 p.m. ET.
Why It Matters
CONMED Corporation's upcoming financial results announcement and conference call provide insights into its performance, influencing market sentiment and stock valuation.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Conmed (CNMD) recently reported earnings. Investors may want to monitor upcoming developments and stock performance following this report.
Why It Matters
Earnings reports can impact stock performance and investor sentiment. Upcoming developments or guidance from Conmed may influence stock volatility and investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
CNMD's growth relies on AirSeal, Buffalo Filter, and BioBrace as supply chains stabilize, despite EPS pressure from tariffs and a GI exit.
Why It Matters
CNMD's reliance on AirSeal, Buffalo Filter, and BioBrace signals key growth areas, but supply chain normalization and external pressures on earnings could impact profitability and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
CONMED Corporation (CNMD) held its Q4 2025 earnings call, discussing financial performance and business updates. Further details on results and forecasts were provided during the call.
Why It Matters
The earnings call provides insights into CNMD's financial performance, guidance, and strategic direction, impacting stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
CONMED Corporation (NYSE: CNMD) reported Q4 2025 sales of $373.2M, up 7.9% YoY. Domestic revenue rose 1.4%, while international revenue increased 17%. Diluted EPS was $0.54.
Why It Matters
CONMED Corporation's Q4 revenue growth, particularly in international markets, indicates strong demand and potential for future expansion, influencing investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About CNMD Stock
What is CONMED Corporation's (CNMD) stock forecast for 2026?
Based on our analysis of 11 Wall Street analysts, CONMED Corporation (CNMD) has a median price target of $43.00. The highest price target is $52.00 and the lowest is $39.00.
Is CNMD stock a good investment in 2026?
According to current analyst ratings, CNMD has 0 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $39.08. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CNMD stock?
Wall Street analysts predict CNMD stock could reach $43.00 in the next 12 months. This represents a 10.0% increase from the current price of $39.08. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is CONMED Corporation's business model?
CONMED Corporation generates revenue by designing, manufacturing, and distributing surgical equipment and medical devices, primarily in orthopedic and general surgery. The company serves a diverse range of healthcare professionals and settings, leveraging sales subsidiaries and distribution networks across approximately 100 countries to reach its customers.
What is the highest forecasted price for CNMD CONMED Corporation?
The highest price target for CNMD is $52.00 from Travis Steed at B of A Securities, which represents a 33.1% increase from the current price of $39.08.
What is the lowest forecasted price for CNMD CONMED Corporation?
The lowest price target for CNMD is $39.00 from Matt O'Brien at Piper Sandler, which represents a -0.2% decrease from the current price of $39.08.
What is the overall CNMD consensus from analysts for CONMED Corporation?
The overall analyst consensus for CNMD is neutral. Out of 11 Wall Street analysts, 0 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $43.00.
How accurate are CNMD stock price projections?
Stock price projections, including those for CONMED Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 2:32 AM UTC